A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
By C. Stover, P. Warrener, D. VanDevanter, David R. Sherman, T. Arain, M. Langhorne, S. W. Anderson, J. A. Towell, Ying Yuan, D. Mcmurray and 3 more. Nature, 2000
1,007 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/3020fa480c44dfec1ea12666a8945203271712c6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- B. Weiner
- D. Moody
- Caroline Colijn
- Megan R. Murray
- T. Cheng
- James E. Galagan
- Maha R. Farhat
- Jeremy D. Zucker
Citations in the corpus
- Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production (2009, background): “PA-824 is a newer nitroimidazopyran drug currently in clinical trials [30].”
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice (2006, background): “PA-824 has been reported to be a prodrug metabolized to its active form by mycobacterium [31].”